- 7. (Once Amended) A protein according to Claim 6 wherein said at least one [of the] coiled coil regions comprises the sequence from position 216 to position 240 of the amino acid sequence shown in SEQ ID No 2.
- 8. (Once Amended) A protein according to Claim[s] 1[-7] wherein [the] said hydrophilic N-terminus comprises the sequence from position 1 to position 280 of the amino acid sequence shown in SEQ ID No 2.
- 10. (Once Amended) A protein according to Claim(s] 1]-9] wherein [the] said nucleotide binding site comprises the sequence of positions/1/14 to 119 of the amino acid sequence shown in SEQ ID No 2.
- 11. (Once Amended) A protein according to Claim[s] 1[-9] wherein the nucleotide binding site comprises the sequence of positions 116, 118 and 120 of the amino acid sequence shown in SEQ ID No 2.
- 12. (Once Amended) A protein according to Claim[s] 1[-11] wherein [the] said EF-hand consensus sequence comprises the sequence from position 16 to 28 of the amino acid sequence shown in SEQ ID No. 2.
- 13. (Once Amended) A protein according to Claim[s] 1[-12] wherein [the] said hydrophobic C-terminus comprises a membrane spanning region.
- 14. (Once Amended) A protein according to Claim[s] 1[-13] wherein there are three coiled coil regions.
- 15. (Once Amended) A protein according to Claim 1[-14] wherein <u>said</u> at least one coiled coil region corresponds to an epimorphin pattern.
- 16. (Once Amended) A protein according to Claim[s] 6 [or 7] wherein [the] said at least one coiled coil region corresponds to an epimorphin pattern.
- 17. (Once Amended) A protein according to [any preceding claim derivable]

  Claim 1 that is derived from a plant, or a mammal.
- 19. (Once Amended) A method of screening for protein-protein interaction comprising the use of a protein of [any preceding claim] Claim 1 and selecting compounds exhibiting said interaction.



- 21. (Once Amended) A [N]nucleic acid encoding the protein of [any one] of Claims 1 [to 18, or 20].
- 22. (Once Amended) A [N]nucleic acid selected from the group consisting of a [comprising the] sequence from positions 18 to 97 shown in SEQ.ID No. 1 [or] and the sequence from positions 77 to 991 shown in SEQ ID No. 3.
- 23. (Once Amended) A [N] nucleic acid sequence encoding for a protein capable of affecting an ABA response and wherein the protein comprises one or more of:
  - (i) a hydrophobic C-terminus;
  - (ii) at least one coiled coil region;
  - (iii) an EF-hand consensus sequence;
  - (iv) a nucleotide binding site, and
- (v) a hydrophilic N-terminus or a variant thereof.
- 24. (Once Amended) A[N] nucleic acid sequence according to Claim 23 wherein the protein is capable of being cleaved by the toxin botchellinium C.
- 25. (Once Amended) A [N]nucleic acid sequence according to Claim[s] 23 [or 24] comprising the sequence from position 18 to position 917 as shown in SEQ ID No 1 or positions 77 to 991 shown in SEQ ID No. 31.
- 26. (Once Amended) A protein encoded by the nucleic acid of [any one of] Claim[s] 22 [to 25].
- 27. (Once Amended) An expression vector comprising the nucleic acid of [any one of] Claim[s] 21 [to 25] operably linked to a promotor.
- 31. (Once Amended) A method of selecting compounds capable of affecting a plant's response to stress comprising screening compounds which bind to the protein of [any one of] Claim[s] 1 [to 18 or 20] and selecting compounds exhibiting said binding.
- 34. (Once Amended) A [N]nucleic acid comprising the sequence shown in SEQ ID No. 5.

35. (Once Amended) A cell comprising the anti-sense sequence to the nucleic acid of [any one of] Claim[s] 21 [to 25].

B

- 37. (Once Amended) A plant, fungus or mammal comprising the anti-sense sequence to the nucleic acid of [any one of] Claim[s] 21 [to 25].
- 38. (Once Amended) A cell, plant, fungus or mammal according to Claim[s] 36 [or 37] wherein the anti- sense sequence comprises the sequence shown in SED ID No. 5.
- 41. (Once Amended) An assay method according to Claim[s] 39 [or 40], wherein the animal cells are oocytes.
- 42. (Once Amended) An assay method according to [any one of] Claim[s] 39 [to 41], wherein the animal cells are from Xenopus.
- 43. (Once amended) An assay method according to [any one of] Claim[s] 39 [to 42], wherein interaction of the signaling component with the ligand causes an increase in free Ca<sup>2+</sup> levels within the cell.
- 44. (Once Amended) An assay method according to [any one of] Claim[s] 39 [to 43], wherein the first detectable physiological effect is an electrical signal.
- 45. (Once Amended) An assay method according to [any one of] Claim[s] 39 [to 44], wherein the signaling component is an ABA signaling component.
- 46. (Once Amended) An assay method according to [any one of] Claim[s] 39 [to 45], wherein the signaling component contained within the cells is derived from one or more nucleotide sequences (e.g. MRNA) injected into the cells.
- 47. (Once Amended) An assay method according to [any one of] Claim[s] 39 [to 46], wherein the assay method includes the further step of observing a second detectable effect.
- 49. (Once Amended) An assay method according to Claim 47 [or Claim 48], wherein the second detectable effect is an electrical signal.
- 50. (Once Amended) An assay method according to Claim[s] 39 [to 49], wherein if a second detectable effect is observed the composition of the plant nucleotide sequence is compared with compositions of non-plant nucleotide sequences to determine if